Research on eating disorders is progressing rapidly. It is now clear that eating disorders are biologically based illnesses, not simple lifestyle choices. Recent genetic work has focused on identifying genes that increase risk for an eating disorder and on gene-environment interactions that may contribute to the onset of an eating disorder. Emerging research suggests that there are significant genetic correlations between several eating disorders and psychiatric and metabolic traits. Brain imaging research is examining altered decision-making around food choice and reward learning in individuals with eating disorders. Other research focuses on understanding how starvation, exercise and binge-purge behaviors change brain reward circuits and gut-brain signaling. This work holds promise for developing novel treatments in the coming years.
The most effective current treatments are behavioral interventions that focus on helping individuals with eating disorders normalize their eating and weight control behaviors. For adolescents with anorexia nervosa, family-based treatment has the best evidence. The focus of effective family-based therapies is on helping parents to support and monitor their child’s meals. For severely ill patients at very low weight, and for many adult patients who are unable to gain weight in outpatient treatment, admission to a specialized residential or hospital-based treatment program can be lifesaving.
The most consistent indicator of relapse after intensive treatment is incomplete weight restoration, so reaching a healthy weight is necessary for recovery from anorexia nervosa. Evidence now suggests that weight gain of three to four pounds a week is safe even for very malnourished patients under close medical monitoring and 24-hour nursing care. Some programs utilize feeding tubes. However, many behavioral specialty programs can achieve four pounds a week weight gain with meal-based feeding alone in most cases. Close outpatient follow-up care following hospitalization is important, as relapse risk is elevated for six months following inpatient treatment.
Emerging treatments with promise, although still in their infancy, include the use of psychedelics, which may assist with reducing the cognitive rigidity associated with anorexia nervosa. Brain stimulation methods, such as repetitive transcranial magnetic stimulation (rTMS), targeting the dorsolateral prefrontal cortex are also of growing interest. Neuroimaging research has suggested abnormal connections in this area of the brain. To date, there are no pharmacological treatments approved for anorexia.
For bulimia nervosa, cognitive behavioral therapy is the most successful outpatient treatment approach. Fluoxetine is currently the only FDA-approved medication; however, other medications, including other antidepressants, show promise in clinical trials.
People with binge eating disorder also respond to cognitive behavioral interventions. Interpersonal therapy is also effective in both bulimia and binge eating disorder. The only FDA-approved pharmacological treatment for BED is lisdexamfetamine. However, research on other medications (such as serotonin reuptake inhibitors and topiramate) shows benefit. There is interest in the use of GLP-1 agonists in reducing binge eating, but more research is needed. Research for the treatment of avoidant restrictive food intake disorder (ARFID) is still relatively limited. However, existing research supports the use of cognitive behavioral therapy with family-based therapy also shows promise in younger children. There are no approved medications for the treatment of ARFID.
In general, one of the most important emerging predictors of treatment success for eating disorders across diagnoses is early behavior change. Even in individuals who are initially highly ambivalent about entering treatment and demoralized by their illness, motivation often increases as they start experiencing progress in controlling their disorder and recognize recovery is within reach.